Effect of New Oropharyngeal Airway on Incidence of Hypoxia During Painless Gastroenteroscopy in Elderly Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-80
SponsorJianbo Wu

About this trial

With the aging of Chinese population, the early screening of gastrointestinal diseases and the promotion and implementation of comfortable medical treatment, more and more elderly patients choose painless gastroenteroscopy for diagnosis and treatment.However, the incidence of anesthesia-related adverse reactions and complications is high in elderly patients.Hypoxemia caused by anesthetic-induced respiratory depression and airway obstruction is a serious complication in painless gastroenteroscopy.Severe hypoxemia not only requires emergency airway intervention, such as mask ventilation or even tracheal intubation, but also leads to the interruption of endoscopic diagnosis and treatment.Advanced age was an independent risk factor for hypoxemia during painless gastroenteroscopy,This study observed the effect of a new type of oropharyngeal ventilation in improving the elderly painless gastroenteroscopy anesthesia hypoxemia and reducing intraoperative airway intervention, so as to evaluate the safety and effectiveness of a new type of nasopharyngeal ventilation in the elderly painless gastrointestinal diagnosis and treatment, and provide clinical reference.

Eligibility criteria

Qualifiers

Age 65-80 years old

written informed consent of patient or family member

painless stomach + colonoscopy

ASA grade I-II

Disqualifiers

Patients with clotting disorders or a tendency to oropharyngeal bleeding, mucosal damage or space occupation, difficulty in placing oropharyngeal airway, etc., who could not perform oropharyngeal airway ventilation;

Upper respiratory tract infections such as mouth, nose or throat;

Fever (core body temperature ≥37.5℃);

a confirmed diagnosis of pregnancy or breastfeeding;

Trial design

Treatments tested in this trial

  • New oropharyngeal airway

Treatment groups

164 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Jianbo Wu

Lead sponsor

Qianfoshan Hospital

Sponsor institution